Dr. Robert Johnson is Owner and Principal
Consultant of Phase X Bio Consulting, providing biopharmaceutical consulting
services.
Dr. Johnson was at Amylin Pharmaceuticals for 8 years. In this role, he was responsible for drug substance development for synthetic and recombinant molecules (exenatide, pramlintide, metreleptin, and phybrid AC165198). He also has been responsible for analytical development, release testing, and long term stability testing for Amylin clinical development programs, including Bydureon, Bydureon dual chamber pen, Bydureon suspension, metreleptin for lipodystrophy, pramlintide/metreleptin for obesity, and phybrid AC165198. He also led the metreleptin integrated development team (IDT) and was the CMC lead to the metreleptin/symlin collaboration full development team (cFDT) as part of the Brystol Myers Squibb-AstraZeneca diabetes alliance.
Prior to joining Amylin, Dr. Johnson worked for 4 years at Genentech Inc. (South San Francisco, CA) and 8 years at Nabi Biopharmaceuticals (Boca Raton, FL). At these companies he held positions in Manufacturing Sciences, Product Development, Quality Control, and Quality Assurance. He received his B.S. in Agricultural and Biological Engineering from Cornell University, C.P.G.S. in Biochemistry from Cambridge University, and Ph.D. in Chemical Engineering from the California Institute of Technology.
Dr. Johnson was at Amylin Pharmaceuticals for 8 years. In this role, he was responsible for drug substance development for synthetic and recombinant molecules (exenatide, pramlintide, metreleptin, and phybrid AC165198). He also has been responsible for analytical development, release testing, and long term stability testing for Amylin clinical development programs, including Bydureon, Bydureon dual chamber pen, Bydureon suspension, metreleptin for lipodystrophy, pramlintide/metreleptin for obesity, and phybrid AC165198. He also led the metreleptin integrated development team (IDT) and was the CMC lead to the metreleptin/symlin collaboration full development team (cFDT) as part of the Brystol Myers Squibb-AstraZeneca diabetes alliance.
Prior to joining Amylin, Dr. Johnson worked for 4 years at Genentech Inc. (South San Francisco, CA) and 8 years at Nabi Biopharmaceuticals (Boca Raton, FL). At these companies he held positions in Manufacturing Sciences, Product Development, Quality Control, and Quality Assurance. He received his B.S. in Agricultural and Biological Engineering from Cornell University, C.P.G.S. in Biochemistry from Cambridge University, and Ph.D. in Chemical Engineering from the California Institute of Technology.